trending Market Intelligence /marketintelligence/en/news-insights/trending/VYRahSWW1fNOCVNBI3SAfg2 content esgSubNav
In This List

Johnson & Johnson to expand coverage of joints drug

Blog

Insight Weekly: US inflation soars; real estate faces slowdown; megadeals drive tech M&A

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Insight Weekly: Path to net-zero; US manufacturing momentum; China's lithium M&A frenzy


Johnson & Johnson to expand coverage of joints drug

Janssen Biotech Inc. sought U.S. FDA approval to expand Simponi Aria's coverage as a treatment for active psoriatic arthritis and active ankylosing spondylitis.

The Johnson & Johnson unit filed two supplemental biologics license applications for the drug, which is already approved as a therapy for adult patients with moderate to severe active rheumatoid arthritis.

Psoriatic arthritis and ankylosing spondylitis affect more than 2 million Americans, Johnson & Johnson noted in a news release.

Arthritis is any disorder that affects joints. Ankylosing spondylitis is a form of arthritis.